ReviewBiomarker research2023
Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?
Review in Biomarker research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Restoring STING expression in soft tissue sarcoma increases activation and function of tumor-infiltrating lymphocytes.Cancer immunology, immunotherapy : CII · 2026Article
- Correlation Between Molecular Genetic Analysis and Nuclear Pleomorphism in Long-Term Recurrent and Metastatic Chordoma.Cancers · 2026Article
- Intimal sarcomas (ISarc) of the cardiac chambers (CC) of the heart and great vessels (GV): a comprehensive genomic profiling (CGP) study.Cardio-oncology (London, England) · 2026Article
- Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma.Frontiers in immunology · 2026Article
- Nutritional biomarkers regulating tumor immune microenvironment in osteosarcoma and as predictors of immune checkpoint inhibitor responses.Frontiers in immunology · 2026Review
- Targeting the osteosarcoma immune microenvironment for improved immunotherapy and translational applications.Discover oncology · 2025Review
- Enhancing prognostic precision: exploring the role of lung immune prognostic index in immunotherapy-treated soft tissue sarcoma patients-a retrospective study.Journal of orthopaedic surgery and research · 2025Article
- Telomere-metabolism-immunity axis in sarcoma: Immune evasion mechanisms and therapeutic strategies.Clinical and translational medicine · 2025Review
- Microsatellite instability and PD-L1 expression in sarcomas: current evidence and clinical perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Blood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy.International journal of cancer · 2025Review
- Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience.Frontiers in immunology · 2025Article
- Impact of comprehensive genomic profiling on the diagnosis and clinical management of malignant mesenchymal tumours.Pathology oncology research : POR · 2025Article
- Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors.Frontiers in immunology · 2025Review
- Article
- Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy.Clinical and translational medicine · 2024Review
- Article
- Immune pathway through endometriosis to ovarian cancer.World journal of clinical oncology · 2024Review
- An ion channel-based prognostic model identified TRPV2 and GJB3 as immunotherapy determinants in pancreatic cancer.Heliyon · 2024Article
- Distinct roles of CD244 expression in cancer diagnosis and prognosis: A pan-cancer analysis.Heliyon · 2024Article
- Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.Molecular cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. Immune checkpoint inhibitors (ICIs) are key agents in cancer immunotherapy, demonstrating improved outcomes in many tumor types. However, most patients with sarcoma do not benefit from treatment, highlighting the need for identification and development of predictive biomarkers for response to ICIs. In this review, we first discuss United States (US) Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biomarkers, as well as the limitations of their use in sarcomas. We then review eight potential predictive biomarkers and rationalize their utility in sarcomas. These include gene expression signatures (GES), circulating neutrophil-to-lymphocyte ratio (NLR), indoleamine 2,3-dioxygenase (IDO), lymphocyte activation gene 3 (LAG-3), T cell immunoglobin and mucin domain-containing protein 3 (TIM-3), TP53 mutation status, B cells, and tertiary lymphoid structures (TLS). Finally, we discuss the potential for TLS as both a predictive and prognostic biomarker for ICI response in sarcomas to be implemented in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.